BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience and Metabolic Research

Executive Summary: BIIE 0246 is a highly selective antagonist of the neuropeptide Y Y2 receptor (Y2R), with an IC₅₀ of 3.3 nM and Ki between 8-15 nM in validated binding assays (APExBIO). It robustly blocks Y2R-mediated presynaptic inhibition in rat hippocampal slices, abolishing NPY-induced suppression of population EPSPs and afterdischarge activity (Fan et al., 2024). BIIE 0246 enables direct assessment of post-prandial satiety and anxiolytic-like behaviors in rodent models, confirming the central role of Y2R in feeding and anxiety regulation (internal review). The compound is highly soluble in DMSO (67.2 mg/ml) and ethanol (23.55 mg/ml), supporting diverse experimental workflows. APExBIO supplies BIIE 0246 (SKU: B6836) as a research-only reagent; long-term solution storage is not recommended (product page).

Biological Rationale

The neuropeptide Y (NPY) system is a conserved signaling pathway that regulates feeding, anxiety, and autonomic functions. The Y2 receptor (Y2R) is a G-protein-coupled receptor predominantly expressed presynaptically in the brain and gastrointestinal tract. Activation of Y2R by endogenous ligands (NPY, PYY_3-36) typically exerts inhibitory control on neurotransmitter release and neural firing. In cardiac tissue, the adipose-neural axis involving NPY and its receptors is implicated in arrhythmogenesis, with increased NPY and epicardial adipose tissue observed in atrial fibrillation patients (Fan et al., 2024). Selective antagonists such as BIIE 0246 are necessary for dissecting the specific contributions of Y2R to these physiological and pathophysiological processes.

Mechanism of Action of BIIE 0246

BIIE 0246 acts as a competitive antagonist at the NPY Y2 receptor. It binds with high affinity (Ki 8-15 nM) to PYY_3-36 sites, preventing endogenous ligand interaction and downstream Gi/o protein signaling (APExBIO). In hippocampal slices, BIIE 0246 abolishes NPY-induced inhibition of primary afterdischarge and population excitatory postsynaptic potentials, confirming blockade of presynaptic Y2R-mediated inhibitory effects. In peripheral models, BIIE 0246 completely inhibits PYY_3-36-induced contraction of rat colon and attenuates the reduction in food intake induced by PYY_3-36, demonstrating physiological antagonism at both central and peripheral Y2Rs (internal content). Importantly, BIIE 0246 does not antagonize Y1 or Y5 receptors at similar concentrations, providing target selectivity.

Evidence & Benchmarks

• BIIE 0246 exhibits a Ki of 8–15 nM for specific PYY_3-36 binding sites in radioligand assays (product spec).
• BIIE 0246 abolishes NPY-induced inhibition of population EPSPs in rat hippocampal slices at 1 μM concentration (in vitro, 25°C, pH 7.4) (Fan et al., 2024).
• In vivo, BIIE 0246 fully blocks PYY_3-36-induced colonic contraction in rat tissue assays (internal review).
• BIIE 0246 attenuates PYY(3-36)-induced reduction in feeding behavior in rodent models, confirming central Y2R involvement in satiety (internal content).
• BIIE 0246 produces anxiolytic-like effects in the elevated plus-maze test in rats, in line with Y2R antagonism (internal content).
• No significant antagonism is observed at Y1 or Y5 receptors up to 10 μM, indicating high selectivity (APExBIO).

Applications, Limits & Misconceptions

BIIE 0246 is validated for use in dissecting presynaptic inhibitory effect blockade, feeding behavior modulation, and anxiety-related circuits. It is also applied in studies of the neuropeptide Y signaling pathway in cardiac models, building on recent findings of the adipose-neural axis in arrhythmogenesis (Fan et al., 2024). The compound's solubility profile enables use in both in vitro and in vivo systems. Researchers should note that BIIE 0246 is strictly for research use; it is not a diagnostic or therapeutic agent.

Common Pitfalls or Misconceptions

• Not active at Y1 or Y5: BIIE 0246 does not antagonize NPY Y1 or Y5 receptors at research-relevant concentrations; it is not a pan-NPY antagonist.
• Not a direct anti-arrhythmic: While it informs the role of Y2R in the adipose-neural axis, BIIE 0246 is not validated as a therapeutic for cardiac arrhythmias (Fan et al., 2024).
• No medical/diagnostic use: The compound is intended exclusively for laboratory research; clinical or diagnostic application is not authorized (APExBIO).
• Long-term solution instability: Prepared solutions of BIIE 0246 are not recommended for extended storage due to potential degradation (APExBIO).
• Solubility limits: While highly soluble in DMSO and ethanol, precipitation may occur in aqueous buffers above recommended concentrations.

This article extends the scope of previous reviews by integrating the latest evidence on Y2R roles in cardiac arrhythmia models. For a deeper mechanistic discussion on translational neuropeptide Y pathway research, see this thought-leadership article; for troubleshooting strategies and use-case optimization, refer to this workflow guide.

Workflow Integration & Parameters

BIIE 0246 (APExBIO, SKU: B6836) is supplied as a white solid (molecular weight 896.06, C₄₉H₅₇N₁₁O₆). It is soluble up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol. Storage at 4°C is recommended; avoid repeated freeze-thaw cycles. For in vitro assays, typical working concentrations range from 10 nM to 1 μM, depending on receptor density and tissue type. For in vivo rodent studies, dosing regimens should be optimized based on administration route and pharmacokinetics; published studies often employ 0.1–1 mg/kg intraperitoneally. Long-term solution storage is not advised. Always consult the product datasheet for up-to-date preparation guidelines.

Conclusion & Outlook

BIIE 0246 represents a benchmark tool for selective NPY Y2 receptor inhibition in neuroscience and metabolic research. Its specificity and reproducibility enable detailed dissection of presynaptic inhibitory mechanisms, feeding behavior, anxiety, and the neurocardiac axis. As emerging data implicate NPY–Y2R signaling in metabolic and cardiovascular disorders, BIIE 0246 will remain essential for hypothesis-driven research and preclinical validation (Fan et al., 2024). For authoritative sourcing and technical support, refer to APExBIO's official BIIE 0246 page.